<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04073407</url>
  </required_header>
  <id_info>
    <org_study_id>AXA1957-002</org_study_id>
    <nct_id>NCT04073407</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Tolerability of AXA1957 in Adolescent Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)</brief_title>
  <official_title>A Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Physiological Effects on Liver Structure and Function of an Amino Acid Food Product, AXA1957, in Adolescent Subjects With Fatty Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axcella Health, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axcella Health, Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, single blind study to determine whether AXA1957, a novel composition of
      amino acids, is safe and well tolerated. Subjects will be adolescents with non-alcoholic
      fatty liver disease (NAFLD), and it will also examine liver biology using blood tests and
      magnetic resonance imaging (MRI).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of study product emergent adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Baseline to week 13</time_frame>
    <description>AEs and SAEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in liver fat as assessed by MRI-PDFF</measure>
    <time_frame>Baseline to week 13</time_frame>
    <description>MRI-PDFF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HOMA-IR</measure>
    <time_frame>Baseline to week 13</time_frame>
    <description>HOMA-IR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma glucose</measure>
    <time_frame>Baseline to week 13</time_frame>
    <description>Plasma Glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma insulin</measure>
    <time_frame>Baseline to week 13</time_frame>
    <description>Plasma insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in alanine aminotransferase (ALT)</measure>
    <time_frame>Baseline to week 13</time_frame>
    <description>ALT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in aspartate aminotransferase (AST)</measure>
    <time_frame>Baseline to week 13</time_frame>
    <description>AST</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>AXA1957</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AXA1957 20.4g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 24g</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>AXA1957</intervention_name>
    <description>Amino acids, food study</description>
    <arm_group_label>AXA1957</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Willing to participate in the study and provide written informed consent.

          -  Male and female adolescent subjects aged 12 to 17 years

          -  Subjects must not have participated in any diet/lifestyle intervention or
             observational studies, or engaged in any body weight altering regimens that resulted
             in body weight fluctuations (i.e. body weight loss or gain by 5%) in the preceding 30
             days prior to Screening.

          -  Non alcoholic fatty liver disease

          -  Diabetes or prediabetes

          -  A screening MRI consistent with liver inflammation and fibrosis

        Key Exclusion Criteria:

          -  Current or history of significant alcohol consumption

          -  History or presence of liver disease (other than NAFLD/NASH)

          -  History or presence of cirrhosis and/or history or presence of hepatic decompensation

          -  Any diabetes other than Type 2

          -  Other poorly controlled medical condition (for example, uncontrolled hypertension with
             a systolic blood pressure &gt; 100 mmHg)

          -  Known sensitivity and/or history of clinically significant food intolerance/allergies
             to proteins (including whey, soy, casein, amino acids, etc.),

          -  Unable or unwilling to adhere to contraception requirements

          -  Any contraindications to a MRI scan

          -  Any other condition that, in the opinion of the Investigator, renders the subject at
             risk for compliance, compromises the well-being of the subject, or hinders study
             completion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saul Faust, MBBS MRCPCH PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southampton</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret Koziel, MD</last_name>
    <phone>857-320-3200</phone>
    <email>regulatory@axcellahealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manu Chakravarthy, MD</last_name>
    <phone>857-320-3200</phone>
    <email>regulatory@axcellahealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal London Children's Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandhia Naik, MbChB PhD FRCPH</last_name>
      <phone>+44 0 20 3594 2473</phone>
      <email>sandhia.naik@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univeristy of Southhampton</name>
      <address>
        <city>Southampton</city>
        <zip>S016 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikki Davis, MD</last_name>
      <phone>+ 44 (0) 23 8120 6883</phone>
      <email>N.Davis@soton.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 27, 2019</study_first_submitted>
  <study_first_submitted_qc>August 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2019</study_first_posted>
  <last_update_submitted>October 9, 2019</last_update_submitted>
  <last_update_submitted_qc>October 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

